Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
X-linked form of cerebellar ataxia.
No HPO annotations are available for this condition.
The phenotypic features of males with fragile X syndrome (FXS) vary in relation to puberty .
Prepubertal features
Source: GeneReviews — "FMR1 Disorders"
FMR1 disorders should be considered in individuals with the following clinical and associated findings.
Fragile X syndrome (FXS)
Males and females with intellectual disability or developmental delay of unknown cause
Males with unexplained autism spectrum disorder and females with unexplained autism spectrum disorder and the presence of an additional indicator: phenotype compatible with FXS; family history of X-linked neurodevelopmental disorders; or premature ovarian failure, ataxia, or tremors in close relatives
No approved treatments are currently available for X-linked cerebellar ataxia. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with an FMR1 disorder, the evaluations summarized in phenotype-specific , , and (if not performed as part of the evaluation that led to diagnosis) are recommended. For all phenotypes, consultation with a clinical geneticist and/or genetic counselor is recommended. Table 6. Fragile X Syndrome: Recommended Evaluations Following Initial Diagnosis
Table 11. Recommended Surveillance for Individuals with Fragile X Syndrome
System/Concern |
|---|
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
34 publications have been identified in PubMed for X-linked cerebellar ataxia. Research spans Case Report / Case Series (36%), Basic Science / Preclinical (24%), and Review / Meta-Analysis (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 12 | 36% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 8:52 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about X-linked cerebellar ataxia
Fragile X-associated tremor/ataxia syndrome (FXTAS)
Source: GeneReviews — "FMR1 Disorders"
Developmental delay/ intellectual disability (DD/ID). The signs of fragile X syndrome (FXS) in early childhood are nonspecific, with DD being an almost universal manifestation among affected individuals. Any child (male or female) with delay of speech, language, or motor development of unknown etiology should be considered for fragile X testing, especially in the presence of a family history of ID and a consistent physical and behavioral phenotype, and the absence of structural abnormalities of the brain or other birth defects . When fragile X molecular genetic testing is used regularly in this large and loosely defined group of unselected males with ID, the yield of positive test results is relatively low (~3%-6%) . In a more recent study, found the yield to be 1.2%. Because chromosome abnormalities and copy number variants have been identified as frequently or more frequently than FMR1 pathogenic variants in individuals with DD or ID who are referred for fragile X testing, microarray testing should be performed as a part of the laboratory evaluation . Conditions to be considered in the differential diagnosis of FXS include those summarized in . Table 5. Disorders to Consider in the Differential Diagnosis of Fragile X Syndrome
Disorder | Gene /Genetic Mechanism | MOI | Clinical Features of Differential Diagnosis Disorder |
|---|---|---|---|
NSD1 | AD | Typical facial appearance; Mild-to-severe learning disability; Behavior problems; Seizures | Overgrowth; Congenital cardiac anomalies; Neonatal jaundice; Renal anomalies |
Scoliosis Prader-Willi syndrome (PWS) | See footnote 1. | See footnote 2. | A small subset of those w/FXS have the hyperphagia obesity characteristic of PWS3; DD cognitive impairment; Temper tantrums, stubbornness, manipulative behavior, obsessive-compulsive traits |
Short stature Autismspectrumdisorder | See footnote 4. | ARADXLMu | Autistic-like behavior |
ADHD | See footnote 5. | ADMu | Hyperactivity |
Fragile XE syndrome (FRAXE) (OMIM 309548) | AFF26(FMR2) | XL | Mild ID (not as severe as is typically seen in FXS) |
Source: GeneReviews — "FMR1 Disorders"
Biomarker and diagnostic research for X-linked cerebellar ataxia has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Development | Complete developmental educational assessments for educational planning | Incl motor, adaptive, cognitive, speech-language eval OT eval |
Behavioral | Comprehensive behavioral neuropsychiatric eval | Evaluate for concentration/attention issues, anxiety, OCD, aggression, depression, /or findings suggestive of ASD. |
Musculoskeletal | Orthopedics/ physical medicine rehab/ PT eval | Evaluate for joint hyperextensibility, pes planus, scoliosis, hypotonia. |
Neurologic | Neurology eval if history of spells that may represent seizures | Evaluate for seizures. Gastrointestinal/ |
Feeding | Gastroenterology/ nutrition/ feeding team evaluation if issues are present | Evaluate for infant feeding issues incl attn to possible gastroesophageal reflux. |
Eyes | Ophthalmology eval | To assess for strabismus |
Ears/Hearing | Otolaryngology/audiology eval | Assess for evidence of recurrent otitis media assoc hearing loss. |
Cardiac | Baseline eval w/cardiologist | Incl echocardiogram for mitral valve prolapse aortic root dilatation |
Sleep | Sleep study if sleep issues are present | Evaluate for sleep apnea. ASD = autism spectrum disorder; OCD = obsessive-compulsive disorder; OT = occupational therapy; PT = physical therapy Table 7. |
Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Recommended Evaluations Following Initial Diagnosis System/Concern | Evaluation | Comment |
Neurologic | Neurologic eval w/movement disorder specialist | — |
Motor | PT | Plan should be to maintain gait assist w/optimal support equipment, if needed. |
Fine motor | OT | Manage tremor, work on assisted daily living, obtain adaptive devices, if needed. Psychiatric/ |
Behavioral | Neuropsychiatric eval | Identify treat any comorbid psychiatric conditions. OT = occupational therapy; PT = physical therapy Table 8. |
FMR1 Primary Ovarian Insufficiency (FXPOI): Recommended Evaluations Following Initial Diagnosis System/Concern | Evaluation | Comment |
Genitourinary | Gynecologic eval | Assess ovarian reserve hormonal markers perform transvaginal ultrasound. |
Psychiatric | Psychological referral | Evaluate for anxiety depression. |
Skeletal | DXA scan | Evaluate for low bone mineral density. |
Endocrine | Thyroid testing | Evaluate for hypothyroidism. DXA = dual-energy x-ray absorptiometry No specific treatment is available. Supportive and symptom-based therapy for children and adults with fragile X syndrome (FXS) is currently provided by the Fragile X Clinical and Research Consortium (FXCRC). |
Source: GeneReviews — "FMR1 Disorders"
FXTAS. Affected individuals should avoid the following:
Typical and atypical antipsychotics with significant anti-dopaminergic effects, which can exacerbate parkinsonism
Metoclopramide, which can exacerbate parkinsonism
Anticholinergic agents, which can exacerbate cognitive complaints
Excessive alcohol, which can increase cerebellar dysfunction and postural instability
Agents with known cerebellar toxicity or side effects (use with caution)
FXPOI. Affected individuals should avoid tobacco products. Tobacco use decreases ovarian reserve and the age of onset of FXPOI. Women who are smokers have, on average, POI onset five years earlier than nonsmokers .
Source: GeneReviews — "FMR1 Disorders"
There are multiple ongoing trials of medication for behavior or drugs targeting the underlying neurobiological mechanism of fragile X syndrome (FXS) based on animal model studies. For example:
Source: GeneReviews — "FMR1 Disorders"
1 trial found
Evaluation
Frequency |
|---|
Eyes | Comprehensive ophthalmologic exam by age 4 yrs to evaluate for strabismus emergence of farsightedness | 2-yr follow up |
Ears | Visualize tympanic membranes. | At each visit |
Dental | Dental exam | Annually |
Cardiovascular | Children: assess for murmur or click; if present, refer to cardiologist. | At each visit Adults: clinical exam, EKG, echocardiogram; refer to cardiologist if needed (e.g., if murmur is heard). |
Respiratory | Assess for signs of obstructive sleep apnea perform sleep study if needed. | At each visit Gastrointestinal |
Musculoskeletal | Children: physical exam at birth; refer to orthopedics, physiotherapy, orthotics if needed. | Every 4 mos Adults: physical exam; refer to orthopedics, physiotherapy if needed. |
Recommended Surveillance for Individuals with FXTAS System/Concern | Evaluation | Frequency |
Cardiovascular | Age-appropriate blood pressure cholesterol monitoring | Ongoing aggressive management of CV risk factors recommended, given diffuse white matter injuries in FXTAS. |
Cognition | MOCA survey1 | Annual |
Psychiatric features | Beck DepressionInventory or similar | Annual CV = cardiovascular 1. |
Source: GeneReviews — "FMR1 Disorders"
Laboratory research |
8 |
24% |
Research summaries | 4 | 12% |
Disease patterns and progression | 4 | 12% |
Testing and diagnosis research | 3 | 9% |
New treatment approaches | 2 | 6% |
Menden B (2026). [PMID: 41690933](https://pubmed.ncbi.nlm.nih.gov/41690933/). *Nature communications*. [Epidemiology / Natural History]
Tassone F (2026). [PMID: 41917775](https://pubmed.ncbi.nlm.nih.gov/41917775/). *Annals of clinical and translational neurology*. [Epidemiology / Natural History]
Erdoğan HA (2026). [PMID: 41777520](https://pubmed.ncbi.nlm.nih.gov/41777520/). *Noro psikiyatri arsivi*. [Gene Therapy / Novel Therapeutics]
Kim JH (2026). [PMID: 41787648](https://pubmed.ncbi.nlm.nih.gov/41787648/). *International journal of stem cells*. [Basic Science / Preclinical]
Anderson CJ (2026). [PMID: 41934608](https://pubmed.ncbi.nlm.nih.gov/41934608/). *Human molecular genetics*. [Gene Therapy / Novel Therapeutics]
Xiao C (2026). [PMID: 42033631](https://pubmed.ncbi.nlm.nih.gov/42033631/). *Cerebellum*. [Case Report / Case Series]
Nakagawa Y (2026). [PMID: 42105168](https://pubmed.ncbi.nlm.nih.gov/42105168/). *Cerebellum*. [Case Report / Case Series]
Sharma R (2025). [PMID: 39971645](https://pubmed.ncbi.nlm.nih.gov/39971645/). *Parkinsonism & related disorders*. [Case Report / Case Series]
Sharma R (2025). [PMID: 39947991](https://pubmed.ncbi.nlm.nih.gov/39947991/). *Parkinsonism & related disorders*. [Basic Science / Preclinical]
Xu F (2025). [PMID: 38969962](https://pubmed.ncbi.nlm.nih.gov/38969962/). *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. [Case Report / Case Series]